Consideration of early stopping and other challenges in monitoring the Heart and Estrogen/progestin Replacement Study

Data Monitoring in Clinical Trials: A Case Studies Approach

Volumn , Issue , 2006, Pages 236-247

  Hulley, Stephen B ^a   Grady, Deborah ^b   Vittinghoff, Eric ^a   Williams, O Dale ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889848462     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-30107-0_22     Document Type: Chapter

References (18)

1. Barrett-Connor E, Grady D. 1998. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Pub Health 19:55-72.
2. Mendelsohn ME, Karas RH. 1999. The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811.
3. PEPI Writing Group. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208.
4. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. 1995. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 85:304-313.
5. Grady D, Appgate W. Bush T, et al. 1998. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials 19:314-335.
6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605-613.
7. Lan K K G, De Mets DL, Halperin M. 1984. More flexible sequential and non-sequential designs in long-term clinical trials. Commun Stat Theory Method 3:2339-2354.
8. Coronary Drug Project Research Group. 1981. Practical aspects of decision making in clinical trials: The Coronary Drug Project as a case study. Control Clin Trials 1:363-376.
9. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. 1996. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348:977-980.
10. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. 1996. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348:981-983.
11. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. 1996. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348:983-987.
12. Grady D, Hulley SB, Furberg CD. 1997. Venous thromboembolic events associated with hormone replacement therapy. JAMA 278:477.
13. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. 2002. Cardiovascular outcomes during 6.8 years of hormone therapy: HERS II. JAMA 288:49-57.
14. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, et al. 2002. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: HERS II. JAMA 288:58-66.
15. USPHS Task Force. 2002. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions. Ann Intern Med 137:834-839.
16. Mosca L, Collins P, Herrington D. 2001. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 104:499-503.
17. Hersh AL, Stefanick ML, Stafford RS. 2004. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53.
18. WHI Study Group. 2002. Risks and benefits of estrogen plus progestin in health postmenopausal women. JAMA 288:321-333.